Crossmark

Nitisinone treatment protect hereditary tyrosinemia type I patients against inflammation, DNA and protein oxidative damage by decreasing succinylacetone levels

Crossref DOI link: https://doi.org/10.1007/s11011-025-01719-2

Published Online: 2025-09-26

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mascarello, Roberta Barbizan https://orcid.org/0009-0006-1662-4602
Faverzani, Jéssica Lamberty https://orcid.org/0000-0002-3695-6827
Lopes, Franciele Fátima https://orcid.org/0000-0002-5022-3742
Tedesco, Luísa Maria Bosquetti https://orcid.org/0000-0002-5223-1041
Böttcher, Ana Kalise https://orcid.org/0009-0009-4654-8534
Wajner, Moacir https://orcid.org/0000-0001-6372-1807
Vargas, Carmen Regla https://orcid.org/0000-0002-2135-0654
Funding

Funding for this research was provided by:

Fundo de incentivo à pesquisa e eventos do Hospital de Clínicas de Porto Alegre

Conselho Nacional de Desenvolvimento Científico e Tecnológico
License Information

Text and Data Mining valid from 2025-09-26

Version of Record valid from 2025-09-26
More Information

Article History

Received: 6 February 2025

Accepted: 19 September 2025

First Online: 26 September 2025

Declarations

:

: This study was approved by the Ethics Committee of Hospital de Clínicas de Porto Alegre, RS, Brazil, and the informed consent was obtained according to the guidelines of the committee (project number 2022 − 0391).

: Informed consent was obtained from all individual participants, or from legal guardians, included in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below